Point72 Asset Management
CYTK icon

Point72 Asset Management’s Cytokinetics CYTK Stock Holding History

Point72 Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Buy
28,000
+1,900
+7% +$121K ﹤0.01% 2365
2025
Q4 		$1.66M Buy
26,100
+6,100
+31% +$379K ﹤0.01% 2586
2025
Q3 		$1.1M Buy
+20,000
New +$824K ﹤0.01% 1666
2025
Q1 		– Sell
-100,000
Closed -$4.7M – 2135
2024
Q4 		$4.7M Buy
100,000
+80,000
+400% +$4.15M 0.01% 971
2024
Q3 		$1.06M Hold
20,000
– – ﹤0.01% 1396
2024
Q2 		$1.08M Sell
20,000
-27,500
-58% -$1.66M ﹤0.01% 1253
2024
Q1 		$3.33M Sell
47,500
-452,500
-91% -$35M 0.01% 1101
2023
Q4 		$41.7M Buy
+500,000
New +$18.1M 0.1% 257

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Asset Management's CYTK Position: Q1 2026 in Review

Point72 Asset Management opened a new position in Cytokinetics (CYTK) in Q1 2026: 626,102 shares worth $41.3M. The stake represents 0.05% of the portfolio and ranks #455 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in CYTK as recently as Q3 2025.

Point72 Asset Management first reported a position in CYTK in Q2 2019 and has held it in 24 quarters since. The position peaked at $69.2M in Q1 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Point72 Asset Management held 626,102 shares of Cytokinetics worth $41.3M as of Q1 2026.
  • Cytokinetics was a new Point72 Asset Management position in Q1 2026.
  • Cytokinetics made up 0.05% of Point72 Asset Management's portfolio in Q1 2026, its #455 holding.
  • Point72 Asset Management first reported a position in Cytokinetics in Q2 2019 and has held it in 24 quarters since.
  • Point72 Asset Management's Cytokinetics position peaked at $69.2M in Q1 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.